| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
EDAP TMS S.A.$4.32
0 (0%)
D 32Pipeline Score MedTech · Clinical
Market Cap
161.17 M
EPS
-0.82
P/E Ratio
-
Value Trade
244.68 K
SEC Financials
Q1 2026Dilution Risk
35%Revenue
17.81 M
R&D Expenses
2.60 M
Operating CF
-2.97 M
Total Assets
72.06 M
Total Liabilities
61.96 M
Equity
10.10 M
D/E Ratio
12,345
4.62 %
Week
25.36 %
1 Month
-9.09 %
3 Month
76.23 %
6 Month
-34.75 %
5 Year
-53.51 %
All Time
Cash Data
Cash Position
15.01 M
Monthly Burn
991.00 K
Runway
13.1 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
55.88 K
52 Week Range
1.21 - 5.05
% held by Insiders
0.53 %
% held by Institutions
38.86 %
Enterprise Value
173.95 M
Total Shares
37.48 M
Short %
0.36 %
Float Shares
37.41 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D32
Pipeline Score $33M
Pipeline ValueValuation Signal
1
Drugs Scored0.2x
rNPV / MCap Top 40%
Micro Cap (rank 548 of 911)
Percentile RankEDAP TMS S.A. faces pipeline headwinds (32/100), with $444M risk-adjusted pipeline value, led by sargramostim in Recurrent Prostate Cancer (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| sargramostim Monoclonal antibody | Recurrent Prostate Cancer | Phase 1 | NCT02250014 | 17% | $444M | COMPLETED | 19 | - | - | Dec 21, 2020 | - | Feb 9, 2022 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in EDAP
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
EDAP Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How EDAP ranks across every disease it competes inCompetitive Position is a premium feature
See how EDAP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial